FDA Breakthrough
Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
Nice Insight
PR-M08-19-NI-071Aug 26, 2019
Phase II Study
Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health
Eiger
PR-M08-18-NI-057Aug 15, 2018